var data={"title":"Instant glucose and intravenous dextrose: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Instant glucose and intravenous dextrose: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6009?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-drug-information\" class=\"drug drug_general\">see &quot;Instant glucose and intravenous dextrose: Drug information&quot;</a> and <a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-patient-drug-information\" class=\"drug drug_patient\">see &quot;Instant glucose and intravenous dextrose: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50306670\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pfizer Extended Expiration Dates for Emergency Syringe Shortages</span>\n      <span class=\"collapsible-date\">- updated November 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has alerted health care providers of extended expiration dates for certain injectable drug products manufactured by Hospira (a Pfizer company) which may be used beyond the labeled expiration dates to assist with the ongoing critical shortages of injectable drugs used in critical care. Select lot numbers of atropine sulfate injection, dextrose 50%, epinephrine injection, and sodium bicarbonate are eligible for use beyond the labeled expiration date if they have been and will continue to be stored according to the labeled conditions<b>. </b></p>\n        <p style=\"text-indent:0em;\">Further information, including specific products, lot numbers, and extended expiration dates, may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPGtnB1wPEGG5AqBctyC78FXNni9GZNAqH+dg03OunIQVFis/VBQ2KMfj5sKJ1X0d3K8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=13222\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm</a><b>.</b></p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158911\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dextrose Thermoject System [DSC];</li>\n      <li>Glucose Nursette [OTC];</li>\n      <li>Glutol [OTC];</li>\n      <li>Glutose 15 [OTC] [DSC];</li>\n      <li>Glutose 45 [OTC] [DSC];</li>\n      <li>Good Start 5% Glucose Water [OTC];</li>\n      <li>Insta-Glucose [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058953\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Insulin</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Oral Hypoglycemic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Fluid Replacement, Enteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Fluid Replacement, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hyperglycemic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hyperkalemia, Adjunctive Treatment Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Intravenous Nutritional Therapy</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442285\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoglycemia: Note:</b> Doses may be repeated in severe cases:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.2 g/kg/dose (2 mL/kg/dose of D10W); followed by a continuous IV infusion at a rate of 5 to 8 <b>mg</b>/kg/minute to maintain plasma glucose &ge;40 to 50 mg/dL (Adamkin 2011; Fanaroff 2013; Lilien 1980); if plasma glucose concentrations remain low, increase infusion in 2 <b>mg</b>/kg/minute increments; if rates &gt;12 to 14 <b>mg</b>/kg/minute are required further work up may be needed (Fanaroff 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>PALS Guidelines</i> (Kleinman 2010): IV, IO: 0.5 to 1 g/kg/dose (5 to 10 mL/kg/dose of D10W)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Limited data available: Dextrose gel 40%: GA &ge;35 weeks, PNA: &le;48 hours: Buccal: 0.2 g/kg/dose (0.5 mL/kg of 40% dextrose gel) massage into the buccal mucosa; if still hypoglycemic after 30 minutes or if hypoglycemia recurs later, repeat dose; may repeat up to 6 doses over 48 hours. Dosing is based on a randomized, double-blind, placebo-controlled trial of 237 at-risk neonates (treatment group: n=118); dextrose gel was shown to be a more effective hypoglycemic treatment than feeding alone during the first 48 hours; treatment failure rates in the dextrose group were 12% vs 24% in the placebo group (Harris 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition:</b> Dextrose component (ASPEN 2002; ASPEN Pediatric Nutrition Support Core Curriculum [Corkins 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm neonates: IV: Initial: 6 to 8 <b>mg</b>/kg/minute; daily increase: 1.4 to 1.7 <b>mg</b>/kg/minute; usual goal: 10 to 14 <b>mg</b>/kg/minute; maximum daily rate: 18 <b>mg</b>/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term neonates: IV: Initial:  6 to 8 <b>mg</b>/kg/minute; daily increase: 3.5 <b>mg</b>/kg/minute; usual goal: 10 to 14 <b>mg</b>/kg/minute; maximum daily rate: 18 <b>mg</b>/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia, treatment: </b>Limited data available: <b>Note:</b> Experts suggest using a ratio of 4 g of dextrose for every 1 unit of insulin when assessing bolus doses of dextrose (AAP [Hegenbarth 2008]); and for continuous IV dextrose infusion, a ratio range of 2 to 4 g of dextrose for every 1 unit of insulin (Cloherty 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.4 g/kg/dose (4 mL/kg/dose of D10W) combined with regular insulin (AAP [Hegenbarth 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: 0.2 g/kg/dose (2 mL/kg of D10W) in combination with regular insulin followed by a continuous infusion 0.2 to 0.4  g/kg/<b>hour</b> (2 to 4 mL/kg<b>/hour</b> of D10W) (Cloherty 2012); dextrose in combination with insulin has been reported to decrease potassium levels in premature neonates (n=7; GA: &le;28 weeks) (Malone 1991)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058947\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-drug-information\" class=\"drug drug_general\">see &quot;Instant glucose and intravenous dextrose: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypoglycemia: Note:</b> Doses may be repeated in severe cases:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, IO:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Dextrose 25% solution: 0.5 to 1 g/kg/dose (2 to 4 mL/kg/dose of 25% solution); maximum dose: 25 g/dose (AAP [Hegenbarth 2008]; PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Dextrose 50% solutions: 0.5 to 1 g/kg/dose (1 to 2 mL/kg/dose of 50% solution); maximum dose: 25 g/dose (AAP [Hegenbarth 2008]; PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Children and Adolescents: 15 to 20 g as a single dose; repeat in 15 minutes if hypoglycemia persists (ADA 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperkalemia, treatment:</b>  Infants, Children, and Adolescents: IV: 0.5 to 1 g/kg/dose (using 25% or 50% solution) combined with regular insulin over 15 to 30 minutes; dose may be repeated; in some cases, a continuous IV infusion may be necessary. <b>Note:</b> Usual ratio is 1 unit insulin for every 4 to 5 g dextrose. In adults, the usual dose is 10 units of insulin mixed with 25 g of dextrose (50 mL of D50W) administered over 15 to 30 minutes (ACLS [Vanden Hoek 2010]; Fuhrman 2011; Hegenbarth 2008; Lehnhardt 2011; Masilamani 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parenteral nutrition:</b> IV: Dextrose component (ASPEN 2002; ASPEN Pediatric Nutrition Support Core Curriculum [Corkins 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;1 year: Initial: 6 to 8 <b>mg</b>/kg/minute; daily increase: 3.5 <b>mg</b>/kg/minute increments; usual goal: 10 to 14 <b>mg</b>/kg/minute; maximum daily rate: 18 <b>mg</b>/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 10 years: Initial: 3 to 6 <b>mg/</b>kg/minute; daily increase: 2 to 3 <b>mg</b>/kg/minute; usual goal: 8 to 10 <b>mg</b>/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;10 years and Adolescents: Initial: 2.5 to 3 <b>mg</b>/kg/minute; daily increase: 1 to 2 <b>mg</b>/kg/minute; usual goal: 5 to 6 <b>mg</b>/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypoglycemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 10 to 25 g (40 to 100 mL of 25% solution or 20 to 50 mL of 50% solution); repeat as needed in severe cases</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 4 to 20 g as a single dose; may repeat if necessary; alternatively, the American Diabetes Association (ADA) recommends 15 to 20 g as a single dose; repeated in 15 minutes if self-monitoring of blood glucose shows continued hypoglycemia (ADA 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia (adjunctive treatment):</b> IV: 25 g dextrose (50 mL D50W) over 5 to 30 minutes; administer with regular insulin 10 units; repeat as needed (AHA [Vanden Hoek 2010]; Allon 1990)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158895\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glutose 15: 40% (37.5 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glutose 45: 40% (112.5 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glutose 15: 40% (37.5 g [DSC]) [lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Insta-Glucose: 77.4% (31 g) [contains fd&amp;c red #40, methylparaben, propylparaben, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glutol: 100 g/180 mL (180 mL) [lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dextrose Thermoject System: 5% (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/mL (10 mL); 5% (25 mL, 50 mL, 100 mL, 150 mL, 250 mL, 500 mL, 1000 mL); 10% (250 mL, 500 mL, 1000 mL); 20% (500 mL); 30% (500 mL); 40% (500 mL); 50% (50 mL, 500 mL, 1000 mL [DSC], 2000 mL [DSC]); 70% (500 mL, 1000 mL, 2000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glucose Nursette: 5% (59 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Good Start 5% Glucose Water: 5% (88.7 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158884\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058958\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Must be swallowed to be absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: For IV administration only, not SubQ or IM. Maximum concentration for peripheral administration is 12.5%; in emergency situations, 25% dextrose has been used peripherally in infants and children and 50% dextrose in adolescents; for direct IV infusion, administer over 1 minute at a  rate not to exceed 200 mg/kg; continuous infusion rates vary with tolerance and range from 4.5 to 15 <b>mg</b>/kg/minute; hyperinsulinemic neonates may require up to 15 to 25 <b>mg</b>/kg/minute infusion rates</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vesicant (at concentrations &ge;10%); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (Hurst 2004); elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buccal: Neonate: Dry mouth with gauze; massage gel into buccal mucosa (Harris 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158909\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Stable at room temperature; protect from freezing and extreme heat. Store oral dextrose in airtight containers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058957\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fluid/calorie replacement:</b> 5% and 10% injection: Provision of calories and fluid replacement (FDA approved in all ages)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition:</b> &ge;10% solutions: Infusion after admixture with amino acids for nutritional support (FDA approved for all ages)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoglycemia:</b></p>\n    <p style=\"text-indent:0em;margin-left:2em;\">\n      <i>Parenteral:</i></p>\n    <p style=\"text-indent:0em;margin-left:4em;\">25% (Hypertonic) solution: Treatment of acute symptomatic episodes of hypoglycemia to restore depressed blood glucose levels (FDA approved in neonates and older infants)</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">50% (Hypertonic) solution: Treatment of insulin-induced hypoglycemia (hyperinsulinemia or insulin shock) (FDA approved in adults)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">\n      <i>Oral:</i> Treatment of hypoglycemia (OTC products [gel, liquid, tablets]: FDA approved in adults; refer to product specific information regarding FDA approval in pediatric patients)</p>\n    <p style=\"text-indent:0em;\">Has also been used in the treatment of hyperkalemia (25% and 50% injection in combination with insulin)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158927\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Glutose may be confused with Glutofac</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (hypertonic solutions &ge;20%) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Inappropriate use of low sodium or sodium-free intravenous fluids (eg D<sub>5</sub>W, hypotonic saline) in pediatric patients can lead to significant morbidity and mortality due to hyponatremia (ISMP 2009).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158926\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Localized phlebitis, phlebitis, venous thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, loss of consciousness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration, glycosuria, hyperglycemia, hyperosmolar syndrome, hypervolemia, hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hypersensitivity reaction (including anaphylaxis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158901\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Injectable: Hypersensitivity to corn or corn products; hypertonic solutions in patients with intracranial or intraspinal hemorrhage, diabetic coma, or delirium tremens, especially if dehydrated; severe dehydration; glucose-galactose malabsorption syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158887\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: Vesicant (at concentrations &ge;10%); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperglycemia: An unexpected rise in blood glucose level in an otherwise stable patient may be an early symptom of infection. Rapid administration of hypertonic solutions may produce significant hyperglycemia, glycosuria, and shifts in electrolytes; this may result in dehydration, hyperosmolar syndrome, coma, and death especially in patients with chronic uremia or carbohydrate intolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Severe hypersensitivity, including anaphylaxis, has been reported with dextrose infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypokalemia: Administration of potassium free IV dextrose solutions may result in significant hypokalemia, particularly if highly concentrated dextrose solutions are used; monitor closely and/or add potassium to dextrose solutions for patients with adequate renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyponatremia: Administration of low sodium or sodium-free IV dextrose solutions may result in significant hyponatremia or water intoxication in pediatric patients; monitor serum sodium concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; hyperglycemia and glycosuria may be functions of the rate of administration of dextrose; to minimize these effects, reduce the rate of infusion; addition of insulin may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperkalemia: The use of dextrose with insulin for the treatment of hyperkalemia achieves a rapid reduction in serum potassium concentrations by redistributing potassium intracellularly; however, this effect is transient (lasts up to 2 hours) and does not remove potassium body stores. Consider the use of other therapies aimed at increasing potassium elimination (eg, sodium polystyrene sulfonate, hemodialysis) (Elliott 2010; Khilnani 1992; Kraft 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Very low birth weight infants: Excessive or rapid dextrose administration in very low birth weight infants has been associated with increased serum osmolality and possible intracerebral hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Oral forms: Do not use oral forms in unconscious patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Abrupt withdrawal: Rebound hypoglycemia may be associated with abrupt withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Hypertonic solutions (&gt;10%) may cause thrombosis if infused via peripheral veins; administer hypertonic solutions via a central venous catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Parenteral nutrition: Patients receiving parenteral nutrition may be at risk of infections, refeeding syndrome, and parenteral nutrition associated liver disease (especially preterm infants).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299170\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158890\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13222&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158892\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (injection, infusion) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14207749\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with dextrose injection. In women with hyperemesis gravidarum who cannot tolerate oral liquids for prolonged periods or who are clinically dehydrated, intravenous hydration that includes dextrose is recommended. Due to potential maternal complications, enteral therapy is preferred over parenteral if nutrition support is required. Total parenteral nutrition (which may include dextrose) should be reserved for use in women with severe nausea and vomiting not responsive to medical therapy (ACOG 153 2015). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058952\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum and urine glucose concentrations; serum electrolytes, I &amp; O, caloric intake</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158886\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Dextrose, a monosaccharide, is a source of calories and fluid for patients unable to obtain an adequate oral intake; may decrease body protein and nitrogen losses; promotes glycogen deposition in the liver. When used in the treatment of hyperkalemia (combined with insulin), dextrose stimulates the transient uptake of potassium by cells, especially in muscle tissue, lowering serum potassium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158900\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Treatment of hypoglycemia: Oral: 10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum effect: Treatment of hyperkalemia: IV: 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapidly from the small intestine by an active mechanism </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Metabolized to carbon dioxide and water </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 40 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058963\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1 g dextrose IV =  3.4 kcal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1 g glucose monohydrate = 1 g anhydrous dextrose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osmolarity:  Dextrose 10%:  505 mOsm/L; Dextrose 25%: 1,330 mOsm/L; Normal body fluid: 310 mOsm/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323104\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Glucose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (10): $2.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Glutose 15 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40% (37.5 g): $3.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Insta-Glucose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">77.4% (31 g): $4.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (100 mL): $2.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (500 mL): $6.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (500 mL): $13.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30% (500 mL): $13.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40% (500 mL): $14.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50% (50 mL): $9.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70% (2000 mL): $20.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Glucose Nursette Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (59 mL): $1.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Good Start 5% Glucose Water Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (88.7 mL): $1.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158903\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ardeanutrisol G (CZ);</li>\n      <li>Dextrabbott (MX);</li>\n      <li>Dextralpha (MX);</li>\n      <li>Dextrevit (MX);</li>\n      <li>Dextrogel (GB);</li>\n      <li>Diasol 5 (KR);</li>\n      <li>Fima D5 (IN);</li>\n      <li>Fluidex-5 (QA);</li>\n      <li>Glucocemin (ES);</li>\n      <li>Glucolin (AR);</li>\n      <li>Glucosada (PT);</li>\n      <li>Glucosado (PT);</li>\n      <li>Glucose Braun (PL);</li>\n      <li>Glucosteril (DE, FI, RU);</li>\n      <li>Glucosum (PL);</li>\n      <li>Glucotem (AR);</li>\n      <li>Glukoza (PL);</li>\n      <li>Glukoza Braun (PL);</li>\n      <li>Hluran CL (UA);</li>\n      <li>Infusan D (IN);</li>\n      <li>Infusol D10 (LK);</li>\n      <li>Injectio Glucosi (PL);</li>\n      <li>Isodex (HU);</li>\n      <li>Kissimin (AR);</li>\n      <li>Marivelle (PH);</li>\n      <li>Nutrosa (AR);</li>\n      <li>Rapilose (GB);</li>\n      <li>Wida (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adamkin DH and Committee on Fetus and Newborn, &quot;Postnatal Glucose Homeostasis in Late-Preterm and Term Infants,&quot; <i>Pediatrics</i>, 2011, 127(3):575-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/21357346/pubmed\" target=\"_blank\" id=\"21357346\">21357346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. <i>Kidney Int</i>. 1990;38(5):869-872.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/2266671/pubmed\" target=\"_blank\" id=\"2266671\">2266671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 5. Glycemic Targets. <i>Diabetes Care</i>. 2016;39(suppl 1):S39-S46. doi: 10.2337/dc16-S008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/26696679/pubmed\" target=\"_blank\" id=\"26696679\">26696679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASPEN Board of Directors and the Clinical Guidelines Task Force, &quot;Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,&quot; <i>JPEN J Parenter Enteral Nutr</i>, 2002, 26(1 Suppl):1-138.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corkins MR, Balint J, Corkins KG, Bobo E, Plogsted S, Yaworski, JA, eds. A<i>.S.P.E.N. Pediatric Nutrition Support Handbook</i>. 2nd ed. Silver Spring, MD: American Society for Enteral and Parenteral Nutrition; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department Health and Human Services, Food Drug Administration, &quot;Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,&quot; <i>Federal Register</i>, 2000, 65(17):4103-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dex4 (dextrose) [prescribing information]. Allegan MI: Perrigo; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dex4 (dextrose) [prescribing information]. Alpharetta GA: CanAm Care, LLC; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dex4 liquid (dextrose) [prescribing information]. Allegan MI: Perrigo; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    70% Dextrose injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dextrose injection [prescribing information]. Lake Forest, IL: Hospira Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dextrose injection [prescribing information]. Lake Forest, IL: Hospira Inc; June 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    10% Dextrose injection [prescribing information]. Lake Forest, IL: Hospira Inc; June 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    50% Dextrose injection [prescribing information]. Lake Forest, IL: Hospira Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia. <i>CMAJ</i>. 2010;182(15):1631-1635.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/20855477/pubmed\" target=\"_blank\" id=\"20855477\">20855477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fanaroff AA, Fanaroff JM, eds. <i>Klaus &amp; Fanaroff's Care of the High-Rick Neonate</i>, 6th ed. Philadelphia, PA: Elsevier Saunders; 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/20855477/pubmed\" target=\"_blank\" id=\"20855477\">20855477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier Health; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glutose 15 (dextrose) [prescribing information]. Minneapolis, MN: Paddock Laboratories; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2013;382(9910):2077-2083.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/24075361/pubmed\" target=\"_blank\" id=\"24075361\">24075361</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA; American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infant Dextrose 25% (dextrose) [prescribing information]. Lake Forest, IL: Hospira Inc; February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice, &quot;Plain D5W or Hypotonic Saline Solutions Post-Op Could Result in Acute Hyponatremia and Death in Healthy Chlidren,&quot; ISMP Medication Safety Alert, August 13, 2009. Available at http://www.ismp.org/Newsletters/acutecare/articles/20090813.asp</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khilnani P. Electrolyte abnormalities in critically ill children. <i>Crit Care Med</i>. 1992;20(2):241-250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/1737458/pubmed\" target=\"_blank\" id=\"1737458\">1737458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. <i>Am J Health Syst Pharm</i>. 2005;62(16):1663-1682.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/16085929/pubmed\" target=\"_blank\" id=\"16085929\">16085929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. <i>Pediatr Nephrol</i>. 2011;26(3):377-384.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/21181208/pubmed\" target=\"_blank\" id=\"21181208\">21181208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lilien LD, Pildes RS, Srinivasan G, Voora S, Yeh TF. Treatment of neonatal hypoglycemia with minibolus and intraveous glucose infusion. <i>J Pediatr</i>. 1980;97(2):295-298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/7400902/pubmed\" target=\"_blank\" id=\"7400902\">7400902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone TA. Glucose and insulin versus cation-exchange resin for the treatment of hyperkalemia in very low birth weight infants. <i>J Pediatr</i>. 1991;118(1):121-123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/1986079/pubmed\" target=\"_blank\" id=\"1986079\">1986079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. <i>Arch Dis Child</i>. 2012;97(4):376-380.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/21920871/pubmed\" target=\"_blank\" id=\"21920871\">21920871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al, &quot;Safe Practices for Parenteral Nutrition,&quot; <i>JPEN J Parenter Enteral Nutr</i>, 2004, 28(6):S39-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care [published corrections appear in <i>Circulation</i>. 2011;123(6):e239 and <i>Circulation</i>. 2011;124(15):e405]. <i>Circulation</i>. 2010;122(18 suppl 3):s829-s861.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-pediatric-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13222 Version 158.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50306670\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158911\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058953\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442285\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058947\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158895\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F158884\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058958\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F158909\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058957\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F158927\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F158926\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158901\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158887\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299170\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F158890\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158892\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14207749\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058952\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158886\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F158900\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1058963\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323104\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F158903\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13222|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-drug-information\" class=\"drug drug_general\">Instant glucose and intravenous dextrose: Drug information</a></li><li><a href=\"topic.htm?path=instant-glucose-and-intravenous-dextrose-patient-drug-information\" class=\"drug drug_patient\">Instant glucose and intravenous dextrose: Patient drug information</a></li></ul></div></div>","javascript":null}